# Acerta Pharma BV clinical trials: 41 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 41 trials with Acerta Pharma BV as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Acerta Pharma BV: 41 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/acerta-pharma-bv

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 41
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 41, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| December 1, 2021 | NCT05140096 | A Study to Evaluate the Effect of Pharmacokinetics (PK) of Acalabrutinib and Its Active Metabolite (ACP-5862) When Administered Alone and... | Acerta Pharma BV | Phase 1 | Completed | Healthy Volunteers | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05140096) |
| June 7, 2021 | NCT04914936 | A Study to Evaluate the One-way Interaction of Calcium Carbonate, Omeprazole, or Rifampin on ACP-196 | Acerta Pharma BV | Phase 1 | Completed | Healthy Participants | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04914936) |
| May 27, 2021 | NCT04905043 | A Study to Evaluate the Effect of Gastric pH on Acalabrutinib Pharmacokinetics (PK) in Healthy Adult Participants | Acerta Pharma BV | Phase 1 | Completed | Healthy Volunteers | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04905043) |
| May 26, 2021 | NCT04901923 | A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, Food Effects, and Drug-drug Interactions of ACP-196 in Healthy Participants | Acerta Pharma BV | Phase 1 | Completed | Healthy Participants | 59 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04901923) |
| May 24, 2021 | NCT04898101 | A Study to Evaluate the Effect of \[14C\]Acp-196 (Acalabrutinib) in Healthy Adult Participants | Acerta Pharma BV | Phase 1 | Completed | Healthy Volunteers | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04898101) |
| May 7, 2021 | NCT04876807 | A Study to Evaluate the Effect of an Acidic Formulation of Acalabrutinib (ACP-196), Acidic Beverage, or Grapefruit Juice on the... | Acerta Pharma BV | Phase 1 | Completed | Healthy Volunteers | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04876807) |
| April 30, 2021 | NCT04867980 | A Study to Evaluate the Effect of ACP-196 on the Heart Rate-corrected QT Interval in Healthy Adult Participants | Acerta Pharma BV | Phase 1 | Completed | Healthy Volunteers | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04867980) |
| April 30, 2021 | NCT04867941 | A Study to Evaluate the Effect of Hepatic Insufficiency on the Pharmacokinetics (PK) of ACP-196 | Acerta Pharma BV | Phase 1 | Completed | Hepatic Insufficiency | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04867941) |
| August 28, 2020 | NCT04529772 | A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) | Acerta Pharma BV | Phase 3 | Active not recruiting | Diffuse Large B-Cell Lymphoma | 611 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04529772) |
| August 4, 2020 | NCT04497948 | Acalabrutinib Study With Best Supportive Care in Participants Hospitalized With COVID-19 | Acerta Pharma BV | Phase 1 | Terminated | COVID-19 | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04497948) |
| May 30, 2019 | NCT03968848 | Investigate the Influence of Severe Hepatic Impairment on the Pharmacokinetics of Acalabrutinib and Its Metabolite | Acerta Pharma BV | Phase 1 | Completed | Hepatic Impairment, Hepatic Insufficiency, Healthy Subjects | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03968848) |
| February 11, 2019 | NCT03836261 | Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy... | Acerta Pharma BV | Phase 3 | Active not recruiting | Chronic Lymphocytic Leukemia | 984 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03836261) |
| May 17, 2018 | NCT03527147 | Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study) | Acerta Pharma BV | Phase 1 | Completed | NHL, DLBCL, Non-hodgkin's Lymphoma, Diffuse Large B Cell Lymphoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03527147) |
| November 1, 2017 | NCT03328273 | A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) | Acerta Pharma BV | Phase 1 | Active not recruiting | Chronic Lymphocytic Leukemia | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03328273) |
| July 2, 2017 | NCT03205046 | A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies | Acerta Pharma BV | Phase 1/2 | Terminated | DLBCL, Richter Syndrome | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03205046) |
| November 25, 2016 | NCT02972840 | A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL | Acerta Pharma BV | Phase 3 | Active not recruiting | Lymphoma, Mantle Cell | 635 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02972840) |
| November 22, 2016 | NCT02970318 | A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL | Acerta Pharma BV | Phase 3 | Active not recruiting | Chronic Lymphocytic Leukemia | 310 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02970318) |
| April 13, 2016 | NCT02735876 | A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle... | Acerta Pharma BV | Phase 3 | Withdrawn | Mantle Cell Lymphoma | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02735876) |
| March 24, 2016 | NCT02717624 | A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL | Acerta Pharma BV | Phase 1 | Active not recruiting | Mantle Cell Lymphoma (MCL) | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02717624) |
| March 24, 2016 | NCT02717611 | A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy | Acerta Pharma BV | Phase 2 | Active not recruiting | Chronic Lymphocytic Leukemia | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02717611) |
| October 27, 2015 | NCT02586857 | A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM) | Acerta Pharma BV | Phase 1/2 | Active not recruiting | Glioblastoma Multiforme | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02586857) |
| October 7, 2015 | NCT02570711 | Phase 2, Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Metastatic Pancreatic Cancer | Acerta Pharma BV | Phase 2 | Terminated | Metastatic Pancreatic Cancer | 3 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02570711) |
| September 1, 2015 | NCT02537444 | Acalabrutinib (ACP-196) Alone and in Combination With Pembrolizumab in Ovarian Cancer (KEYNOTE191) | Acerta Pharma BV | Phase 2 | Completed | Ovarian Cancer | 78 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02537444) |
| June 23, 2015 | NCT02477696 | Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL) | Acerta Pharma BV | Phase 3 | Active not recruiting | Chronic Lymphocytic Leukemia | 533 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02477696) |
| June 19, 2015 | NCT02475681 | Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL | Acerta Pharma BV | Phase 3 | Completed | Chronic Lymphocytic Leukemia | 535 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02475681) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 17 |
| Phase 1/2 | 6 |
| Phase 2 | 11 |
| Phase 3 | 7 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 23 |
| Active not recruiting | 14 |
| Terminated | 3 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Leukemia, Lymphocytic, Chronic, B-Cell | 12 |
| Lymphoma, Non-Hodgkin | 5 |
| Lymphoma, Mantle-Cell | 5 |
| Multiple Myeloma | 3 |
| Lymphoma, Large B-Cell, Diffuse | 3 |
| Lymphoma | 3 |
| Hepatic Insufficiency | 2 |
| Leukemia, Prolymphocytic | 2 |
| Waldenstrom Macroglobulinemia | 2 |
| Pancreatic Neoplasms | 2 |
| Lymphoma, Follicular | 2 |
| Leukemia | 2 |
| Carcinoma, Non-Small-Cell Lung | 1 |
| Lymphoma, B-Cell | 1 |
| Neoplasms | 1 |
| Lymphoproliferative Disorders | 1 |
| Lymphatic Diseases | 1 |
| Squamous Cell Carcinoma of Head and Neck | 1 |
| Lymphoma, B-Cell, Marginal Zone | 1 |
| Glioblastoma | 1 |
| COVID-19 | 1 |
| Ovarian Neoplasms | 1 |
| Recurrence | 1 |
| Chromosome 17 deletion | 1 |
| Leukemia, B-Cell | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Window installers in the United States](https://specstream.ai/data/businesses/window-installers/united-states)
- [Whiskey bars in the United States](https://specstream.ai/data/businesses/whiskey-bars/united-states)
- [Web design firms in the United States](https://specstream.ai/data/businesses/web-design-firms/united-states)
- [Water delivery companies in the United States](https://specstream.ai/data/businesses/water-delivery-companies/united-states)
- [Vietnamese restaurants in the United States](https://specstream.ai/data/businesses/vietnamese-restaurants/united-states)
- [Vehicle parts manufacturers in the United States](https://specstream.ai/data/businesses/vehicle-parts-manufacturers/united-states)
